HK1201253A1 - Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof - Google Patents

Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof Download PDF

Info

Publication number
HK1201253A1
HK1201253A1 HK15101876.0A HK15101876A HK1201253A1 HK 1201253 A1 HK1201253 A1 HK 1201253A1 HK 15101876 A HK15101876 A HK 15101876A HK 1201253 A1 HK1201253 A1 HK 1201253A1
Authority
HK
Hong Kong
Prior art keywords
deuterium
enriched
perillyl alcohol
alcohol
iso
Prior art date
Application number
HK15101876.0A
Other languages
English (en)
Chinese (zh)
Inventor
Thomas Chen
Daniel Levin
Satish Pupalli
Original Assignee
Neonc Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/566,731 external-priority patent/US8916545B2/en
Application filed by Neonc Technologies Inc. filed Critical Neonc Technologies Inc.
Publication of HK1201253A1 publication Critical patent/HK1201253A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15101876.0A 2011-11-21 2012-11-21 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof HK1201253A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161562105P 2011-11-21 2011-11-21
US61/562,105 2011-11-21
US13/566,731 US8916545B2 (en) 2010-08-27 2012-08-03 Pharmaceutical compositions comprising POH derivatives
US13/566,731 2012-08-03
PCT/US2012/066379 WO2013119304A2 (en) 2011-11-21 2012-11-21 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof

Publications (1)

Publication Number Publication Date
HK1201253A1 true HK1201253A1 (en) 2015-08-28

Family

ID=48948152

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101876.0A HK1201253A1 (en) 2011-11-21 2012-11-21 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof

Country Status (8)

Country Link
EP (1) EP2782894A4 (enExample)
JP (2) JP2015502352A (enExample)
KR (1) KR20150000469A (enExample)
CN (1) CN103946202A (enExample)
BR (1) BR112014012180A2 (enExample)
CA (1) CA2856403A1 (enExample)
HK (1) HK1201253A1 (enExample)
WO (1) WO2013119304A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945334B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏醇衍生物及其制备和应用
CN104945333B (zh) * 2014-03-27 2018-02-02 沈阳药科大学 紫苏醇类似物及其制备和应用
CN104945335B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏胺类化合物及其制备和应用
CN104945336B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏酸甲酯含氮衍生物及其制备和应用
JP7325425B2 (ja) * 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク. 血液脳関門を透過性にする方法
CN116789530B (zh) * 2023-05-16 2025-12-19 杭州师范大学 一种紫苏醇酚类衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272441A (en) * 1980-03-13 1981-06-09 Fmc Corporation Preparation of carbamates
WO2002076404A2 (en) * 2001-03-23 2002-10-03 Protarga, Inc. Fatty alcohol drug conjugates
US20060104997A1 (en) * 2001-12-11 2006-05-18 Constantinides Panayiotis P Monoterpene compositions and uses thereof
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
KR20070051258A (ko) * 2004-06-23 2007-05-17 호프만 로버트 에프 표적화되는 산화적 치료 제형의 화상 치료에서의 용도
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
EP2081565A2 (en) * 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
WO2010091198A1 (en) * 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes
EP2898883B1 (en) * 2010-08-27 2016-11-23 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
CN101979378B (zh) * 2010-10-13 2012-06-27 中国科学院上海有机化学研究所 一种手性γ-内酰胺化合物的合成方法

Also Published As

Publication number Publication date
JP2018035148A (ja) 2018-03-08
WO2013119304A2 (en) 2013-08-15
BR112014012180A2 (pt) 2017-05-30
KR20150000469A (ko) 2015-01-02
JP2015502352A (ja) 2015-01-22
WO2013119304A3 (en) 2013-10-03
EP2782894A4 (en) 2015-03-11
CN103946202A (zh) 2014-07-23
EP2782894A2 (en) 2014-10-01
CA2856403A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
WO2012027693A3 (en) Pharmaceutical compositions comprising poh derivatives
WO2013119304A3 (en) Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
EP4374929A3 (en) Methods and devices for using isoperillyl alcohol
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
CR20140108A (es) Compuesto de ciclopropanoamina
CL2012001714A1 (es) Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras.
DOP2010000011A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CL2013000481A1 (es) Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
WO2016130800A3 (en) Pharmaceutical compositions comprising perillyl alcohol derivatives
MX383077B (es) Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.
WO2012092421A3 (en) Composition for intravascular delivery of therapeutic composition
EP4613333A3 (en) Pharmaceutical compositions comprising akt protein kinase inhibitors
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
PE20150345A1 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo
WO2012002773A3 (en) Phenylcarbamate compound and muscle relaxant containing the same
WO2015009742A3 (en) Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
CO2019008657A2 (es) Composición intranasal que comprende betahistina
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
WO2013037985A8 (en) Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders